BIOLARGO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOLARGO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $12.23M | Apr 1, 2024 |
| FY2016 | Dec 31, 2016 | $281.1K | Mar 30, 2017 |
| FY2015 | Dec 31, 2015 | $127.6K | Mar 30, 2016 |
| FY2014 | Dec 31, 2014 | $111.5K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $167.9K | Mar 31, 2015 |
| FY2013 | Apr 12, 2013 | $100.0K | Apr 1, 2014 |
| FY2013 | Dec 31, 2012 | $65.5K | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | $156.2K | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | $156.8K | Apr 6, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $516.2K | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $281.1K | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $127.6K | Mar 30, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $7.85M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $6.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.23M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $916.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $621.0K | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $193.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $175.2K | Mar 16, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | ($3.69M) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($2.53M) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($5.33M) | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | ($3.95M) | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | ($5.74M) | Apr 6, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.86M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($4.33M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($4.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.39M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.78M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($7.58M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.70M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($6.41M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($5.90M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($4.93M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.59M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $2.88M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $2.28M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.37M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.34M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.47M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.72M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $1.63M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.38M | Mar 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.77M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $9.30M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $8.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.73M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.17M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.47M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.14M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.31M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $4.43M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $3.71M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.30M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($3.21M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($2.37M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.76M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.94M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.15M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.42M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($3.89M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($4.28M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($3.72M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $28.7K | Mar 16, 2018 |
| FY2012 | Dec 31, 2011 | $3.7K | Mar 29, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.31M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $10.51M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $8.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.86M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.02M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.62M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $3.19M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $1.50M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.11M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.79M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.46M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $4.00M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.18M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.80M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.31M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $4.91M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.88M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.04M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.85M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $6.84M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.88M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.65M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.86M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.15M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.50M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($4.10M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.33M) | Mar 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($161.28M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($149.50M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($147.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($143.59M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($139.12M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($132.04M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($123.49M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($111.72M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($101.21M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($91.92M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.88M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.55M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $3.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $962.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $716.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $655.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $655.0K | Mar 31, 2020 |
| FY2019 | Dec 31, 2017 | $990.0K | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | $1.91M | Mar 29, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.08M | Mar 4, 2026 |
| FY2024 | Dec 31, 2024 | $1.08M | Mar 31, 2025 |
| FY2016 | Dec 31, 2016 | $5.86M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $3.25M | Mar 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 292.95M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 278.46M | Apr 1, 2024 |
| FY2016 | Dec 31, 2016 | 92.98M | Mar 30, 2017 |
| FY2014 | Dec 31, 2014 | 82.91M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 75.12M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 70.71M | Apr 1, 2014 |
| FY2012 | Dec 31, 2011 | 59.24M | Mar 29, 2013 |